What is GlycoMimetics?
Headquartered in Rockville, Maryland, GlycoMimetics specializes in the discovery and development of glycomimetic drugs. The company leverages its expertise in carbohydrate chemistry to create small-molecule inhibitors that target selectins and other proteins involved in disease progression. Its lead candidates, including rivipansel and GMI-1271, are designed to disrupt the cellular interactions that drive vaso-occlusive crises and hematologic malignancies. Through strategic research and development collaborations, most notably with Pfizer Inc., the firm maintains a robust pipeline aimed at transforming the standard of care for patients suffering from debilitating chronic and acute conditions.
How much funding has GlycoMimetics raised?
GlycoMimetics has raised a total of $288.8M across 7 funding rounds:
Series A
$9.6M
Series B
$15.4M
Series C
$38M
Stock Offering
$57.4M
Corporate Investment
$20M
Stock Offering
$20M
Stock Offering
$128.4M
Series A (2004): $9.6M with participation from Anthem Capital Management, Maryland Department of Business and Economic Development, New Enterprise Associates, Alliance Technology Ventures, Novartis Venture Fund, and PTV Sciences
Series B (2006): $15.4M led by Maryland Department of Business and Economic Development, PTV Sciences, New Enterprise Associates, Alliance Technology Ventures, Novartis Venture Fund, and Anthem Capital Management
Series C (2009): $38M supported by Alliance Technology Ventures, Novartis Venture Fund, Anthem Capital, New Enterprise Associates, and Genzyme Ventures
Stock Issuance/Offering (2014): $57.4M featuring Undisclosed
Corporate Investment (2015): $20M backed by Pfizer Inc.
Stock Issuance/Offering (2016): $20M with participation from Undisclosed
Stock Issuance/Offering (2018): $128.4M led by Undisclosed
Key Investors in GlycoMimetics
New Enterprise Associates
Established in 1977 and headquartered in Menlo Park, California, New Enterprise Associates is a venture capital firm focused on helping entrepreneurs build businesses.
Novartis Venture Fund
Novartis is a global pharmaceutical manufacturer specializing in developing and producing innovative medications and healthcare solutions across multiple therapeutic areas.
Alliance Technology Ventures
Alliance Technology Ventures is a venture capital firm focused on private company investments in the semiconductor, communication component, and life science industries.
What's next for GlycoMimetics?
Looking ahead, the strategic deployment of the $128.4M capital infusion will be pivotal for GlycoMimetics as it pushes its clinical programs through late-stage trials. The company is expected to prioritize the advancement of its E-selectin and CXCR4 antagonists, while simultaneously exploring new therapeutic applications for its galectin inhibitors. As the firm matures, its focus will likely shift toward regulatory milestones and potential commercialization strategies. The continued support from institutional investors and the strength of its existing research partnerships provide a stable foundation for the company to navigate the complexities of the biopharmaceutical landscape and deliver long-term value to stakeholders.
See full GlycoMimetics company page
